Related references
Note: Only part of the references are listed.Double-Blind, Randomized, Phase 2 Trial of Maintenance Sunitinib Versus Placebo After Response to Chemotherapy in Patients With Advanced Urothelial Carcinoma
Petros D. Grivas et al.
CANCER (2014)
Long-Term Efficacy and Safety Outcomes of Modified (Simplified) MVAC (Methotrexate/Vinblastine/Doxorubicin/Cisplatin) as Frontline Therapy for Unresectable or Metastatic Urothelial Cancer
Andrea Necchi et al.
CLINICAL GENITOURINARY CANCER (2014)
Phase II study of everolimus in metastatic urothelial cancer
Matthew I. Milowsky et al.
BJU INTERNATIONAL (2013)
A Phase II Safety and Efficacy Study of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Pazopanib in Patients With Metastatic Urothelial Cancer
Roberto Pili et al.
CLINICAL GENITOURINARY CANCER (2013)
Gemcitabine, Cisplatin, and Sunitinib for Metastatic Urothelial Carcinoma and as Preoperative Therapy for Muscle-Invasive Bladder Cancer
Matthew D. Galsky et al.
CLINICAL GENITOURINARY CANCER (2013)
Phase II Study of Gemcitabine, Carboplatin, and Bevacizumab in Patients With Advanced Unresectable or Metastatic Urothelial Cancer
Arjun V. Balar et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers
E. Seront et al.
ANNALS OF ONCOLOGY (2012)
Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial
Andrea Necchi et al.
LANCET ONCOLOGY (2012)
Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity
J. Bellmunt et al.
ANNALS OF ONCOLOGY (2011)
Targeting Activin Receptor-Like Kinase 1 Inhibits Angiogenesis and Tumorigenesis through a Mechanism of Action Complementary to Anti-VEGF Therapies
Dana D. Hu-Lowe et al.
CANCER RESEARCH (2011)
Phase II Trial of Cisplatin, Gemcitabine, and Bevacizumab As First-Line Therapy for Metastatic Urothelial Carcinoma: Hoosier Oncology Group GU 04-75
Noah M. Hahn et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Phase II Study of Sunitinib in Patients With Metastatic Urothelial Cancer
David J. Gallagher et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Prognostic Factors in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract Experiencing Treatment Failure With Platinum-Containing Regimens
Joaquim Bellmunt et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium
Guru Sonpavde et al.
LANCET ONCOLOGY (2010)
Phase 2 Trial of Sorafenib in Patients With Advanced Urothelial Cancer A Trial of the Eastern Cooperative Oncology Group
Robert Dreicer et al.
CANCER (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis
Marion Scharpfenecker et al.
JOURNAL OF CELL SCIENCE (2007)
TGFβ:: the molecular Jekyll and Hyde of cancer
Brian Bierie et al.
NATURE REVIEWS CANCER (2006)
Edmonton symptom assessment scale: Italian validation in two palliative care settings
C Moro et al.
SUPPORTIVE CARE IN CANCER (2006)
In vitro tumoral progression of human bladder carcinoma:: Role for TGFβ
P Champelovier et al.
EUROPEAN UROLOGY (2005)
Activin receptor-like kinase 1 is implicated in the maturation phase of angiogenesis
S Lamouille et al.
BLOOD (2002)
Activin receptor-like kinase 1 modulates transforming growth factor-β1 signaling in the regulation of angiogenesis
SP Oh et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Share Paper
